Ascend Laboratories, LLC received FDA approval Tuesday for the generic version of Fingolimod Hydrochloride (Gilenya), potentially intensifying generic competition in the autoimmune market segment as patent protections for the brand-name drug begin to expire. The oral product is manufactured for major pharmaceutical marketing companies, signaling a significant shift in market access for patients as cost pressures increase for both payers and providers.